Revolutionary CRISPR Gene Therapy Cuts ‘Bad’ Cholesterol and Triglycerides by Half in Early Human Trial

A pioneering one-time infusion of CRISPR gene-editing therapy has safely halved levels of harmful low-density lipoprotein (LDL) cholesterol and triglycerides in a small group of adults, marking a major milestone in the pursuit of durable treatments for heart disease. The breakthrough results, announced November 8, 2025, at the American Heart Association conference and published in The New England Journal of Medicine, highlight the potential of gene editing to transform cardiovascular care by offering an alternative to daily cholesterol-lowering medications.

Key Findings and Study Details

In a Phase 1 clinical trial conducted by CRISPR Therapeutics and led by researchers at the Cleveland Clinic, a single intravenous infusion of CTX310—a CRISPR-Cas9 based therapy—targeted and disabled a liver gene known as ANGPTL3. This gene regulates levels of LDL cholesterol and triglycerides in the blood, both of which are significant risk factors for atherosclerotic cardiovascular disease (ASCVD).

Among 15 participants with lipid disorders resistant to conventional treatments, those receiving the highest dose experienced an average reduction of approximately 50% in both LDL cholesterol and triglycerides within two weeks post-treatment. These effects persisted throughout the 60-day monitoring period, with ongoing follow-up studies planned to assess longer-term outcomes.

“This is the first therapy to achieve such substantial reductions in both LDL and triglycerides simultaneously,” said Dr. Luke Laffin, lead cardiologist at the Cleveland Clinic. “Our findings suggest a durable, one-time genetic intervention could potentially replace the need for daily pills or monthly injections in managing high-risk lipid profiles.” The study reported no serious adverse events related to the treatment during the short-term follow-up, signaling a promising safety profile in this early phase.​

Expert Perspectives and Commentary

Cardiology experts not directly involved in the trial have expressed cautious optimism. Dr. Steven Nissen, a cardiologist at the Cleveland Clinic and principal investigator of the trial, emphasized the significance: “We have never had anything that could reduce both LDL and triglycerides by approximately 50% with a single treatment. These results are unprecedented and could represent a paradigm shift in lipid management.”

However, experts also underscore the necessity for rigorous long-term surveillance. CRISPR-based gene editing permanently alters DNA, so monitoring for unforeseen effects, including potential off-target genetic changes or immune responses, is essential. The FDA typically recommends up to 15 years of follow-up for such therapies to ensure safety.​

Context and Background

Elevated LDL cholesterol, often dubbed “bad cholesterol,” contributes to plaque buildup in arteries, increasing the risk of heart attacks and strokes. High triglycerides also independently raise cardiovascular risk and often coexist with elevated LDL cholesterol in mixed lipid disorders.

Current lipid-lowering treatments include statins, PCSK9 inhibitors, and fibrates, which require lifelong adherence and may not be fully effective or tolerable for all patients. The quest for more sustainable treatments has led researchers to explore CRISPR gene editing, a Nobel Prize-winning technology capable of precisely modifying DNA within cells.

Previous studies established that individuals naturally lacking a functional ANGPTL3 gene due to rare mutations have lifelong low cholesterol and triglyceride levels and a remarkably low incidence of heart disease, without harmful side effects. CTX310 mimics this natural mutation by selectively turning off ANGPTL3 in the liver, offering a genetic approach to cardiovascular risk reduction.​

Implications for Public Health

If further research confirms these initial positive findings, CRISPR gene therapy could revolutionize the treatment paradigm for millions of people with high cholesterol and triglycerides, especially those with treatment-resistant or mixed lipid disorders. This single-administration treatment could improve medication adherence, reduce cumulative side effects, and potentially decrease cardiovascular events more effectively.

The broader availability of gene-editing therapies might soon complement traditional approaches, advancing precision medicine in cardiovascular care.

Limitations and Counterarguments

Despite encouraging early data, the small study size and short duration limit conclusions about the long-term efficacy and safety of CTX310. Potential risks include unintended gene edits and immune reactions, which require careful monitoring.

Additionally, cost and accessibility considerations for gene therapies remain challenging, possibly limiting widespread adoption initially.

Regulatory agencies and researchers stress cautious optimism and call for larger Phase 2 and 3 trials with extended follow-up to validate durability and monitor for adverse events before routine clinical use.

What It Means for Readers

For those managing high cholesterol or triglycerides, this development signals hope for new, highly effective treatments in the future. However, current standard therapies remain the cornerstone of treatment today.

Healthy lifestyle choices such as balanced diets, regular exercise, and medication adherence continue to be vital. Patients should consult healthcare professionals before making any changes based on emerging treatments.

Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References